Business Wire

MN-DTN

31.3.2020 15:02:06 CEST | Business Wire | Press release

Share
DTN Protects COVID-19 Responders With Free Weather Services to Healthcare Workers and First Responders Globally

Weather is always a factor when considering the safety of lives and structures, but with the overwhelming response to the COVID-19 crisis and the volatility of spring weather these risks are amplified. Triage tents and other temporary outdoor structures are extremely vulnerable to weather events, as are other lifesaving operations. Hospitals may not be able to relocate patients during hazardous weather and first response efforts may be challenging.

That is why DTN, an independent source of insights, analysis and decision-support solutions, announced today that it is supporting hospitals, medical institutions, public health agencies, and first responders worldwide by offering its premier weather app service WeatherSentry at no cost during the COVID-19 pandemic.

“At DTN we are committed to providing our insights to support those who feed, fuel and protect our world,” said Mike Eilts, DTN senior vice president-weather. “Our healthcare workers and organizations are on the frontlines of protecting citizens worldwide and, in some cases, working in less-than-ideal structures. It is important that they have access to the best weather information available at their fingertips should the need arise, so they can quickly react and ensure the safety of their patients and themselves in the event of severe weather.”

Healthcare workers, hospitals, public health agencies and first responders globally can register for two free months of WeatherSentry. The subscription includes web and mobile app access to professional-grade alerting for mobile positions and fixed locations; real-time lightning display and alerts; severe weather storm tracks via radar; hourly and 15-day forecasts; and access to DTN meteorologists 24 hours a day, seven days a week.

“DTN has long been there, supporting our customers globally with unmatched insights during difficult situations, such as extreme weather events and customers working outdoors,” said Eilts. “We are proud to be providing WeatherSentry to support our world’s healthcare organizations and first responders when they need the information the most.”

Forecast timing and accuracy, as well as real-time alerts are crucial to lessening the impact to lives during dangerous weather situations. WeatherSentry users get access to precise, accurate, and reliable weather information delivered in a single screen, and updated as conditions change.

WeatherSentry is available for Android phone and tablet users at the Google Play store and for iOS devices on the App store once the free subscription has been authorized. To learn more and to sign up for the complimentary service, visit the DTN WeatherSentry for COVID-19 responders page.

About DTN

DTN delivers accurate, objective, real-time, and actionable insights to increase customers’ confidence and support business decisions. In a data-rich world, these actionable insights in weather and financial analytics make sense of the information, drive change in processes and help businesses prosper. DTN empowers agriculture, energy and transportation customers – those who work endlessly to feed, fuel and protect our world. We believe that when our customers are supported with the most reliable and innovative information to the Nth Degree, they prosper and we all win. DTN’s highly accurate and reliable solutions are backed by more than 140 patents. The company publishes Progressive Farmer magazine, the premier publication in agriculture, and is headquartered in Minneapolis, Minnesota.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye